Which has preferable earnings & valuation, CRON or CPH?

Cipher Pharmaceuticals has lower revenue, but higher earnings than Cronos Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cronos Group C$159.54M 9.25 -C$32.78M N/A N/A Cipher Pharmaceuticals C$50.94M 8.39 C$11.41M C$1.19 14.14

Does the media favor DHT.UN or CPH?

In the previous week, DRI Healthcare Trust had 1 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 2 mentions for DRI Healthcare Trust and 1 mentions for Cipher Pharmaceuticals. DRI Healthcare Trust's average media sentiment score of 0.83 beat Cipher Pharmaceuticals' score of 0.00 indicating that DRI Healthcare Trust is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DRI Healthcare Trust 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cipher Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GUD or CPH?

In the previous week, Knight Therapeutics and Knight Therapeutics both had 1 articles in the media. Knight Therapeutics' average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Knight Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cipher Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend THCX or CPH?

Cipher Pharmaceuticals has a consensus target price of C$17.00, suggesting a potential upside of 1.01%. Given Cipher Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Hydropothecary. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hydropothecary 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cipher Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, THCX or CPH?

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hydropothecary N/A N/A N/A N/A N/A Cipher Pharmaceuticals C$50.94M 8.39 C$11.41M C$1.19 14.14

Does the media prefer CPH or TLRY?

In the previous week, Tilray Brands had 1 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 2 mentions for Tilray Brands and 1 mentions for Cipher Pharmaceuticals. Cipher Pharmaceuticals' average media sentiment score of 0.00 beat Tilray Brands' score of -0.10 indicating that Cipher Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cipher Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tilray Brands 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Cipher Pharmaceuticals (CPH) Competitors

C$16.83 0.00 (0.00%)

As of 07/31/2026 04:00 PM Eastern

Compare

CPH vs. CRON, DHT.UN, GUD, THCX, and TLRY

Should you buy Cipher Pharmaceuticals stock or one of its competitors? MarketBeat compares Cipher Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cipher Pharmaceuticals include Cronos Group (CRON), DRI Healthcare Trust (DHT.UN), Knight Therapeutics (GUD), Hydropothecary (THCX), and Tilray Brands (TLRY).

How does Cipher Pharmaceuticals compare to Cronos Group?

Cronos Group (TSE:CRON) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Cipher Pharmaceuticals has a net margin of 60.82% compared to Cronos Group's net margin of -1.29%. Cipher Pharmaceuticals' return on equity of 25.69% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.29%	-0.19%	-3.73%
Cipher Pharmaceuticals	60.82%	25.69%	7.90%

Cronos Group has a beta of 1.126226, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.153706, suggesting that its share price is 15% more volatile than the broader market.

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than Cronos Group. MarketBeat recorded 1 mentions for Cipher Pharmaceuticals and 0 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.40 beat Cipher Pharmaceuticals' score of 0.00 indicating that Cronos Group is being referred to more favorably in the media.

Company	Overall Sentiment
Cronos Group	Neutral
Cipher Pharmaceuticals	Neutral

Cronos Group currently has a consensus price target of C$4.75, indicating a potential upside of 20.25%. Cipher Pharmaceuticals has a consensus price target of C$17.00, indicating a potential upside of 1.01%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts plainly believe Cronos Group is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cipher Pharmaceuticals has lower revenue, but higher earnings than Cronos Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	C$159.54M	9.25	-C$32.78M	N/A	N/A
Cipher Pharmaceuticals	C$50.94M	8.39	C$11.41M	C$1.19	14.14

4.4% of Cronos Group shares are owned by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by company insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Cronos Group beats Cipher Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

DRI Healthcare Trust (TSE:DHT.UN) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

DRI Healthcare Trust has a beta of 0.385191, indicating that its share price is 61% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.153706, indicating that its share price is 15% more volatile than the broader market.

Cipher Pharmaceuticals has lower revenue, but higher earnings than DRI Healthcare Trust. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DRI Healthcare Trust	C$163.77M	5.81	C$9.73M	-C$0.90	N/A
Cipher Pharmaceuticals	C$50.94M	8.39	C$11.41M	C$1.19	14.14

Cipher Pharmaceuticals has a net margin of 60.82% compared to DRI Healthcare Trust's net margin of 5.02%. Cipher Pharmaceuticals' return on equity of 25.69% beat DRI Healthcare Trust's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DRI Healthcare Trust	5.02%	2.06%	4.22%
Cipher Pharmaceuticals	60.82%	25.69%	7.90%

In the previous week, DRI Healthcare Trust had 1 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 2 mentions for DRI Healthcare Trust and 1 mentions for Cipher Pharmaceuticals. DRI Healthcare Trust's average media sentiment score of 0.83 beat Cipher Pharmaceuticals' score of 0.00 indicating that DRI Healthcare Trust is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DRI Healthcare Trust	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cipher Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.8% of DRI Healthcare Trust shares are held by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are held by institutional investors. 0.1% of DRI Healthcare Trust shares are held by company insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

DRI Healthcare Trust presently has a consensus price target of C$24.80, suggesting a potential upside of 43.27%. Cipher Pharmaceuticals has a consensus price target of C$17.00, suggesting a potential upside of 1.01%. Given DRI Healthcare Trust's stronger consensus rating and higher possible upside, analysts clearly believe DRI Healthcare Trust is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cipher Pharmaceuticals beats DRI Healthcare Trust on 10 of the 17 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Knight Therapeutics (TSE:GUD) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Knight Therapeutics presently has a consensus target price of C$9.50, indicating a potential downside of 3.46%. Cipher Pharmaceuticals has a consensus target price of C$17.00, indicating a potential upside of 1.01%. Given Cipher Pharmaceuticals' higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

22.7% of Knight Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 45.6% of Knight Therapeutics shares are owned by insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cipher Pharmaceuticals has a net margin of 60.82% compared to Knight Therapeutics' net margin of 1.10%. Cipher Pharmaceuticals' return on equity of 25.69% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Knight Therapeutics	1.10%	0.73%	0.51%
Cipher Pharmaceuticals	60.82%	25.69%	7.90%

In the previous week, Knight Therapeutics and Knight Therapeutics both had 1 articles in the media. Knight Therapeutics' average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Knight Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cipher Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cipher Pharmaceuticals has lower revenue, but higher earnings than Knight Therapeutics. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Knight Therapeutics	C$510.45M	1.89	-C$30.73M	C$0.06	164.00
Cipher Pharmaceuticals	C$50.94M	8.39	C$11.41M	C$1.19	14.14

Knight Therapeutics has a beta of -0.206788, indicating that its stock price is 121% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.153706, indicating that its stock price is 15% more volatile than the broader market.

Summary

Cipher Pharmaceuticals beats Knight Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Hydropothecary?

Hydropothecary (CVE:THCX) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Cipher Pharmaceuticals has a consensus target price of C$17.00, suggesting a potential upside of 1.01%. Given Cipher Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Hydropothecary.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hydropothecary	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than Hydropothecary. MarketBeat recorded 1 mentions for Cipher Pharmaceuticals and 0 mentions for Hydropothecary. Hydropothecary's average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Hydropothecary	Neutral
Cipher Pharmaceuticals	Neutral

Cipher Pharmaceuticals has a net margin of 60.82% compared to Hydropothecary's net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 25.69% beat Hydropothecary's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hydropothecary	N/A	N/A	N/A
Cipher Pharmaceuticals	60.82%	25.69%	7.90%

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hydropothecary	N/A	N/A	N/A	N/A	N/A
Cipher Pharmaceuticals	C$50.94M	8.39	C$11.41M	C$1.19	14.14

Summary

Cipher Pharmaceuticals beats Hydropothecary on 9 of the 9 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Tilray Brands?

Cipher Pharmaceuticals (TSE:CPH) and Tilray Brands (TSE:TLRY) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.7% of Tilray Brands shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cipher Pharmaceuticals has a beta of 1.153706, indicating that its share price is 15% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 3.0845, indicating that its share price is 208% more volatile than the broader market.

Cipher Pharmaceuticals currently has a consensus target price of C$17.00, indicating a potential upside of 1.01%. Tilray Brands has a consensus target price of C$13.30, indicating a potential upside of 109.78%. Given Tilray Brands' higher possible upside, analysts plainly believe Tilray Brands is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Tilray Brands had 1 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 2 mentions for Tilray Brands and 1 mentions for Cipher Pharmaceuticals. Cipher Pharmaceuticals' average media sentiment score of 0.00 beat Tilray Brands' score of -0.10 indicating that Cipher Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cipher Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tilray Brands	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cipher Pharmaceuticals has a net margin of 60.82% compared to Tilray Brands' net margin of -15.22%. Cipher Pharmaceuticals' return on equity of 25.69% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	60.82%	25.69%	7.90%
Tilray Brands	-15.22%	-8.85%	-1.41%

Cipher Pharmaceuticals has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	8.39	C$11.41M	C$1.19	14.14
Tilray Brands	C$915.45M	0.94	-C$183.24M	-C$1.09	N/A

Summary

Cipher Pharmaceuticals beats Tilray Brands on 9 of the 14 factors compared between the two stocks.

Get Cipher Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPH vs. The Competition

Export

Metric	Cipher Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$427.34M	C$11.71B	C$6.86B	C$12.25B
Dividend Yield	N/A	2.72%	2.59%	6.20%
P/E Ratio	14.14	799.05	282.30	33.59
Price / Sales	8.39	752.17	561.34	9.16
Price / Cash	3.53	14.82	28.60	82.29
Price / Book	3.20	10.36	10.98	4.33
Net Income	C$11.41M	C$2.82B	C$3.49B	C$299.09M
7 Day Performance	2.43%	-0.10%	-0.60%	-0.53%
1 Month Performance	-1.98%	-3.96%	-5.20%	-1.72%
1 Year Performance	38.29%	156.17%	62.01%	32.66%

Cipher Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPH Cipher Pharmaceuticals	0.4189 of 5 stars	C$16.83 flat	C$17.00 +1.0%	+38.3%	C$427.34M	C$50.94M	14.14	5	Gap Down
CRON Cronos Group	2.2455 of 5 stars	C$3.88 -1.0%	C$4.75 +22.4%	+46.8%	C$1.45B	C$159.54M	N/A	450	Gap Up
DHT.UN DRI Healthcare Trust	3.0302 of 5 stars	C$17.50 -1.6%	C$24.80 +41.7%	+22.6%	C$962.78M	C$163.77M	N/A	N/A
GUD Knight Therapeutics	0.4579 of 5 stars	C$9.69 +0.1%	C$9.50 -2.0%	+59.5%	C$951.36M	C$510.45M	161.50	725
THCX Hydropothecary	N/A	C$5.30 +6.6%	N/A	+0.0%	C$949.11M	N/A	N/A	N/A	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:CPH) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cipher Pharmaceuticals (CPH) Competitors

CPH vs. CRON, DHT.UN, GUD, THCX, and TLRY

How does Cipher Pharmaceuticals compare to Cronos Group?

Summary

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Summary

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Summary

How does Cipher Pharmaceuticals compare to Hydropothecary?

Summary

How does Cipher Pharmaceuticals compare to Tilray Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPH vs. The Competition

Cipher Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cipher Pharmaceuticals (CPH) Competitors

CPH vs. CRON, DHT.UN, GUD, THCX, and TLRY

How does Cipher Pharmaceuticals compare to Cronos Group?

Is CRON or CPH more profitable?

Which has more volatility and risk, CRON or CPH?

Does the media refer more to CRON or CPH?

Do analysts rate CRON or CPH?

Which has preferable earnings & valuation, CRON or CPH?

Do insiders & institutionals have more ownership in CRON or CPH?

Summary

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Which has more risk & volatility, DHT.UN or CPH?

Which has preferable valuation and earnings, DHT.UN or CPH?

Is DHT.UN or CPH more profitable?

Does the media favor DHT.UN or CPH?

Do institutionals & insiders hold more shares of DHT.UN or CPH?

Do analysts recommend DHT.UN or CPH?

Summary

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Do analysts prefer GUD or CPH?

Do institutionals & insiders believe in GUD or CPH?

Is GUD or CPH more profitable?

Does the media refer more to GUD or CPH?

Which has better earnings & valuation, GUD or CPH?

Which has more risk & volatility, GUD or CPH?

Summary

How does Cipher Pharmaceuticals compare to Hydropothecary?

Do analysts recommend THCX or CPH?

Do insiders & institutionals hold more shares of THCX or CPH?

Does the media refer more to THCX or CPH?

Is THCX or CPH more profitable?

Which has stronger valuation and earnings, THCX or CPH?

Summary

How does Cipher Pharmaceuticals compare to Tilray Brands?

Do institutionals and insiders believe in CPH or TLRY?

Which has more volatility and risk, CPH or TLRY?

Do analysts recommend CPH or TLRY?

Does the media prefer CPH or TLRY?

Is CPH or TLRY more profitable?

Which has stronger earnings & valuation, CPH or TLRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPH vs. The Competition

Cipher Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools